Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.

ABSTRACT:

Importance

B-cell-targeting monoclonal antibodies have demonstrated safety and efficacy in multiple sclerosis or anti-aquaporin-4 IgG positive neuromyelitis optica spectrum disorder. However, these therapies do not facilitate drug-free remission, which may become possible with cell-based therapies, including chimeric antigen receptor (CAR) T cells. CAR T-cell therapy holds promise for addressing other antibody-mediated CNS disorders, e.g., MOG-associated disease or autoimmune encephalitis.

Objective

To provide an overview of the current clinical knowledge on CAR T-cell therapy in central nervous system autoimmunity.

Evidence review

We searched PubMed, Embase, Google Scholar, PsycINFO, and clinicaltrials.gov using the terms 'CAR T cell' and 'multiple sclerosis/MS' or '

SUBMITTER: Konitsioti AM 

PROVIDER: S-EPMC11446985 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature